Uncategorized
CMS Issues Preliminary Decision on Unique J Code for Avedro Photrexa® Drug Formulations
WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc., an ophthalmic pharmaceutical and medical device company and world leader in corneal remodeling, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa® drug formulations. Claims submitted with a product specific J code are generally processed more efficiently than claims using a miscellaneous cod